WIRB-Copernicus Group’s Expert WCG Oncology™ Advisory Board Hosts Inaugural Meeting

PRINCETON, N.J., September 10, 2014 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services for clinical research, held the inaugural meeting of its WCG Oncology Advisory Board on September 10 in Princeton, NJ.

The Advisory Board, developed to provide strategic counsel to WCG regarding the changing oncology research landscape, cutting-edge theory, scientific methods, technologies, and study designs, shared updates on the most significant current and future scientific issues in clinical research in oncology.

“As research in oncology becomes more complex- involving personalized medicine, immunotherapy, and companion diagnostics – reviewing bodies must become equally sophisticated,” said WCG’s Chairman and CEO, Donald A. Deieso, PhD. “Through WCG Oncology, our clients are assured that their protocols continue to be measured according to the best science and most recent thinking in the specialty.”

Lindsay McNair, M.D., M.P.H., M.S. Bioethics, Chief Clinical Research Officer and President, Consulting Services, added, “For years, WCG has honed its processes to meet the rigorous demands of oncology research. The cornerstone of our process- as evidenced in the creation of WCG Oncology- is education. We have learned that knowledge transfer and access to expertise are critical to the delivery of high-quality review.”

In attendance at the meeting were WCG Oncology Advisory Board members George Demetri, M.D., of the Dana-Farber Cancer Institute; John Falletta, M.D., of Duke University Medical Center; Arnold Levine, Ph.D., of the Institute for Advanced Study, School of Natural Sciences; and John Niederhuber, M.D., of the Inova Translational Medicine Institute, and Former Head of the National Cancer Institute; and Howard Scher, M.D., of the Memorial Sloan Kettering Cancer Center.

During the meeting, guest speaker Arthur L. Caplan, Ph.D., Director of the Division of Medical Ethics at NYU Langone Medical Center and a WCG Advisory Board member, addressed the unique ethical issues in oncological research, inviting a discussion regarding “Compassionate Use” in cancer research.


About The WIRB-­‐Copernicus Group
The WIRB-Copernicus Group (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG’s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.

WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.

For more information, please visit www.wcgclinical.com.

Download the Press Release
[wpdm_package id=’2371′]